Two doses of Diamyd® show safety in 5-year prevention trial in children at high risk for type 1 diabetes

Diamyd Medical today announces final results from DiAPREV-IT 1, a placebo-controlled clinical pilot trial led by Associate Professor MD Helena Elding Larsson, Lund University, where the diabetes vaccine Diamyd® for the first time is given to a group of individuals at high risk of developing type 1 diabetes. Overall, the results show that the treatment was safe and tolerable, and that fewer subjects than expected, 16 out of 50 compared to expected 25 out of 50, had developed type 1 diabetes in the 5-year follow-up of the trial. However, no significant difference was seen between children